AI-powered Neurodiagnostic Platform for Early Stroke & Alzheimer’s Detection

Project profile curated by GlobalReach Link. Applications are reviewed on a rolling basis.

Stage: SeedRegion: AustraliaIndustry: HealthTechOpen Status: OpenConfidential (NDA): Yes

Project Overview

A neurohealth-focused venture developing a non-invasive diagnostic tool using AI-powered enzyme analysis to detect risk of stroke and Alzheimer’s disease via saliva and serum. Also functions as an incubator supporting health science innovators to accelerate research translation.

Project Goals

Fund Stage:Pre-Seed

Raise Size:USD 500K to 1M

Investment Type:Equity

Skills Needed

This project is particularly suited to experts and teams with the following capabilities:

Financial Advisor / CPA Legal / Solicitor (Cross-border) Investment Consultant / Fundraising

Competitive Advantage

– Saliva-based at-home solution with AI insight – Low-cost strips, high diagnostic accuracy – IP-pending tech with global application

Reasons to Invest & Market Opportunity

Reasons to Invest:

– First-mover in non-invasive home neurodiagnostics
– Strong medical partnerships & clinical pipeline
– High-impact, scalable solution for global aging crisis

Market Opportunity:
– $70B+ diagnostics market – >5500M with dementia; rising global need for early intervention – Scalable to public health & aged care

Problem & Solution

– Early neurodegenerative diseases lack low-cost diagnostics – Saliva-based AI strip detects key biomarkers like D-serine – Non-invasive, portable, cost-efficient

Highlights

– Prototype device completed – Biomarker validated in multi-region cohorts – Academic partnerships in AU, MENA & SE Asia

Apply to Join

Applications are reviewed by the GlobalReach coordination team. Only shortlisted experts will be contacted (NDA for documents).

Apply Now →